CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, today announced that it has expanded its senior management team with the appointment of industry veteran Evan Lippman as the Company’s first Chief Financial and Business Officer.
“We are excited to add a seasoned industry veteran to Aileron’s management team as we advance our p53 targeting oncology drug, ALRN-6924, into the clinic,” said Joseph A. Yanchik III, President and Chief Executive Officer of Aileron Therapeutics. “Evan is a proven leader with deep experience in financial markets, strategic transactions, and business management in the biopharmaceutical and healthcare industries. He has completed billions of dollars worth of business development transactions and created significant commercial growth for a number of blockbuster brands across multiple therapeutic areas. Evan will be a valuable addition to the Aileron leadership team and a key guiding voice in advancing our corporate development and financial initiatives.”
Mr. Lippman commented “Aileron represents a unique proposition among biotechnology companies in that it is at the forefront of Stapled Peptide drug development. I believe the platform, starting with our MDM2/MDMX p53 oncology program, will change drug development strategy and transform the way diseases are treated. I look forward to working with this extraordinary team to build Aileron into a world class company and am pleased to be joining at such an exciting time.”
Mr. Lippman began his career in corporate finance and investment banking, managing equity, debt and M&A processes, working with such companies as Bank of America and Bear Stearns. Prior to joining Aileron, Mr. Lippman was Senior Vice President at EMD Serono, leading the strategic direction of the US Neurology franchise, as well as managing its operations related to sales, marketing and support services. Mr. Lippman joined EMD Serono from AstraZeneca, where he served as Executive Director of the company’s multi-billion dollar brands Crestor® and Nexium®, as well as the general Primary Care Portfolio. While at AstraZeneca, Mr. Lippman also held other roles including Head of US Business Development. Prior to AstraZeneca, he worked at Pfizer as Executive Director, Worldwide Business Development and Strategic Planning. Mr. Lippman holds a Bachelor of Arts in Political Science from Bucknell University, a Bachelor of Arts in Business from Georgia State University, and a Masters in Business Administration from Cornell University.
About Aileron Therapeutics
Aileron Therapeutics is a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform. Aileron’s lead drug development candidate is ALRN-6924, a p53 re-activator for the treatment of cancer. With its proprietary Stapled Peptide platform, Aileron aims to dramatically improve the treatment of a wide range of diseases including cancer, endocrine/metabolic disorders and infectious diseases. For more information, please visit www.aileronrx.com.
Crestor® and Nexium® are registered trademarks of the AstraZeneca group of companies.